Nerve Growth Factor Market Report 2026

The nerve growth factor market size has grown strongly in recent years. It will grow from $1.19 billion in 2025 to $1.28 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to advances in neurobiology research, clinical development of cenegermin, increasing neurological disorder prevalence, expansion of ophthalmology treatment adoption, growth of biologics manufacturing.

The nerve growth factor market size is expected to see strong growth in the next few years. It will grow to $1.71 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to rising incidence of neurodegenerative diseases, expansion of regenerative medicine programs, increasing clinical trials for nerve repair, growth in biologics R&D funding, innovation in NGF delivery systems. Major trends in the forecast period include increasing research in neuroregeneration therapies, rising focus on neurodegenerative disease treatment, expansion of recombinant protein therapeutics, growing clinical use in ophthalmic disorders, increased investment in nerve repair technologies.

The rising incidence of neurological disorders is anticipated to drive the expansion of the nerve growth factor sector in the coming years. Neurological disorders are health conditions that impact the brain, spinal cord, and nerves, arising from structural, biochemical, or electrical abnormalities. The growing occurrence of neurological disorders is attributed to aging populations and improvements in diagnostic technologies. Advances in diagnostic methods enhance the identification and reporting of these disorders, resulting in higher recorded prevalence rates. Nerve growth factor (NGF) is essential for the maintenance, survival, and regeneration of neurons, making it a vital component in managing the prevalence of neurological disorders by supporting neural repair and potentially slowing disease progression. For example, in September 2024, the Australian Institute of Health and Welfare, an Australia-based government organization, reported that dementia cases in Australia are expected to increase from approximately 411,100 in 2023 to 849,300 by 2058. Consequently, the rising prevalence of neurological disorders is fueling the growth of the nerve growth factor sector.

Major companies operating in the nerve growth factor space are concentrating on developing NGF-targeting biologic treatments, including anti-NGF monoclonal antibodies designed to block NGF activity and alleviate chronic pain. An anti-NGF monoclonal antibody attaches to nerve growth factor, preventing it from activating its receptors, which helps diminish pain signaling and inflammatory responses in patients with degenerative or neuropathic disorders. For example, in May 2023, Jiangsu Hengrui Pharmaceuticals, a China-based biopharmaceutical firm, launched SHR-1314, a next-generation anti-NGF monoclonal antibody registered for clinical trials in patients experiencing osteoarthritis-related pain. The therapy offers a highly selective binding profile that lowers NGF-mediated sensitization and a prolonged serum half-life allowing less frequent dosing, aiming to provide sustained pain relief for individuals with chronic joint conditions.

In June 2023, Dompé farmaceutici S.p.A., an Italy-based producer of the first recombinant human nerve growth factor, formed a partnership with FarmaMondo Group to broaden access to Oxervate (cenegermin). Through this collaboration, FarmaMondo becomes the exclusive distributor of Oxervate in selected countries, enhancing availability of this treatment for neurotrophic keratitis patients outside the U.S., Canada, Italy, China, and Switzerland. FarmaMondo Group is a Switzerland-based pharmaceutical services company focusing on specialty care services for rare diseases.

Major companies operating in the nerve growth factor market are Dompé farmaceutici S.p.A., Regeneron Pharmaceuticals Inc., Mimetogen Pharmaceuticals, MimeTech Srl, Herantis Pharma, PainCeptor Pharma, Beike Biotechnology, Akeso Inc., Promega Corporation, Enzo Life Sciences Inc., Alomone Labs, Prospec-Tany Technogene Ltd., CUSABIO Technology LLC, Genexis Biotech Pvt. Ltd., Staidson Beijing BioPharmaceuticals, Biomol GmbH, Sino Biological Inc., PeproTech Inc., Abcam plc, Creative BioMart Inc.

Asia-Pacific was the largest region in the nerve growth factor market in 2025. The regions covered in the nerve growth factor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nerve growth factor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the nerve growth factor market by increasing the cost of imported biologic active ingredients, intermediates, and protein formulation excipients. These impacts have been most pronounced in recombinant NGF therapy segments, particularly in north america and europe. Asia-pacific manufacturers have faced sourcing challenges. However, tariffs have encouraged local biologics manufacturing and strengthened regional biopharmaceutical capabilities.

The nerve growth factor market research report is one of a series of new reports that provides nerve growth factor market statistics, including nerve growth factor industry global market size, regional shares, competitors with a nerve growth factor market share, detailed nerve growth factor market segments, market trends and opportunities, and any further data you may need to thrive in the nerve growth factor industry. This nerve growth factor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nerve growth factor (NGF) is a protein that is vital for the growth, maintenance, and survival of nerve cells, especially sensory and sympathetic neurons. It is important for the development of the nervous system and aids in the regeneration of nerve cells following injury. Nerve growth factor attaches to specific receptors on nerve cells, activating pathways that promote cell survival and differentiation.

The primary types of nerve growth factor include alpha-nerve growth factor (NGF), beta-nerve growth factor (NGF), gamma-nerve growth factor (NGF), and others. Alpha-NGF is a protein crucial for neuron growth, survival, and the development of the peripheral nervous system. It comprises various agents such as cenegermin and others, which are used for multiple indications, including neurodegenerative disorders, spinal cord injuries, eye conditions, epithelial diseases, tissue repair, and more. It is supplied through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and is utilized by different end users, such as hospitals, home care services, specialty clinics, and others.

The nerve growth factor market consists of sales of nerve growth factor protein supplements, nerve growth factor enriched cell culture media, nerve growth factor biomarker detection kits, and diagnostic assays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.